Cargando…

Editorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19

During the past two years, clinical studies have attempted to identify risk factors to predict clinical outcomes following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In July 2021, a study using a high-throughput technique detected autoantibodies to chemokines, cytok...

Descripción completa

Detalles Bibliográficos
Autor principal:	Parums, Dinah V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462125/ https://www.ncbi.nlm.nih.gov/pubmed/34538868 http://dx.doi.org/10.12659/MSM.934766

Ejemplares similares

Editorial: Targets for Disease-Modifying Therapies in Alzheimer’s Disease, Including Amyloid β and Tau Protein
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Reporting Clinical Trials with Important Modifications Due to Extenuating Circumstances, Including the COVID-19 Pandemic: CONSERVE 2021
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution
por: Parums, Dinah V.
Publicado: (2023)

Editorial: The National COVID Cohort Collaborative Consortium Combines Population Data with Machine Learning to Evaluate and Predict Risk Factors for the Severity of COVID-19
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19
por: Parums, Dinah V.
Publicado: (2022)

Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared
por: Parums, Dinah V.
Publicado: (2023)

Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19
por: Parums, Dinah V.
Publicado: (2021)

Editorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems During the COVID-19 Pandemic?
por: Parums, Dinah V.
Publicado: (2021)

Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Long COVID, or Post-COVID Syndrome, and the Global Impact on Health Care
por: Parums, Dinah V.
Publicado: (2021)

Editorial: COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C)
por: Parums, Dinah V.
Publicado: (2021)

Editorial: First Regulatory Approval for Allogeneic Pancreatic Islet Beta Cell Infusion for Adult Patients with Type 1 Diabetes Mellitus
por: Parums, Dinah V.
Publicado: (2023)

Editorial: Multisystem Inflammatory Syndrome in Adults (MIS-A) and the Spectrum of COVID-19
por: Parums, Dinah V.
Publicado: (2021)

Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Registries and Population Databases in Clinical Research and Practice
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-19 Pandemic
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Editorial: A Decline in Influenza During the COVID-19 Pandemic and the Emergence of Potential Epidemic and Pandemic Influenza Viruses
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Current Status of Non-Endemic Global Infections with the Monkeypox Virus
por: Parums, Dinah V.
Publicado: (2022)

Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants
por: Parums, Dinah V.
Publicado: (2022)

Editorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic
por: Parums, Dinah V.
Publicado: (2022)

Editorial: Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). Updated Terminology for the Long-Term Effects of COVID-19
por: Parums, Dinah V.
Publicado: (2023)

Editorial: Artificial Intelligence (AI) in Clinical Medicine and the 2020 CONSORT-AI Study Guidelines
por: Parums, Dinah V.
Publicado: (2021)

Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections
por: Parums, Dinah V.
Publicado: (2021)

Editorial: mRNA Vaccines and Immunotherapy in Oncology: A New Era for Personalized Medicine
por: Parums, Dinah V.
Publicado: (2021)

Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2
por: Parums, Dinah V.
Publicado: (2023)

Editorial: The Increasing Relevance of Case Reports in Medical Education and Clinical Practice – and How to Write Them
por: Parums, Dinah V.
Publicado: (2023)

Editorial: Effective Direct-Acting Antiviral Treatments Support Global and National Programs to Eliminate Hepatitis C
por: Parums, Dinah V.
Publicado: (2023)

Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness
por: Parums, Dinah V.
Publicado: (2023)

Editorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atherosclerotic Cardiovascular Disease (ASCVD)
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Maternal SARS-CoV-2 Infection and Pregnancy Outcomes from Current Global Study Data
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Long-Term Effects of Symptomatic and Asymptomatic SARS-CoV-2 Infection in Children and the Changing Pathogenesis of Common Childhood Viruses Driven by the COVID-19 Pandemic
por: Parums, Dinah V.
Publicado: (2022)

Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Revised World Health Organization (WHO) Terminology for Variants of Concern and Variants of Interest of SARS-CoV-2
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients
por: Parums, Dinah V.
Publicado: (2022)

Editorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030
por: Parums, Dinah V.
Publicado: (2023)

Editorial: The XBB.1.5 (‘Kraken’) Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread
por: Parums, Dinah V.
Publicado: (2023)

Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy
por: Parums, Dinah V.
Publicado: (2021)

Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy
por: Parums, Dinah V.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6t4l8j5un3rr4tk4iem820becd